Larisa H Cavallari

Summary

Affiliation: University of Illinois at Chicago
Country: USA

Publications

  1. pmc Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois, Chicago, IL 60612 7230, USA
    Pharmacogenet Genomics 22:152-8. 2012
  2. pmc Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure
    Adam Bress
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA
    PLoS ONE 8:e71268. 2013
  3. pmc Role of cytochrome P450 genotype in the steps toward personalized drug therapy
    Larisa H Cavallari
    Department of Pharmacy Practice Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
    Pharmgenomics Pers Med 4:123-36. 2011
  4. ncbi request reprint Tailoring drug therapy based on genotype
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, USA
    J Pharm Pract 25:413-6. 2012
  5. pmc The future of warfarin pharmacogenetics in under-represented minority groups
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, 833 South Wood Street, Chicago, IL 60612 7230, USA
    Future Cardiol 8:563-76. 2012
  6. ncbi request reprint Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management
    Larisa M Humma
    Department of Pharmacy Practice, University of Illinois at Chicago, 833 South Wood Street, Room 164, Chicago, IL 60612, USA
    Am J Health Syst Pharm 59:1241-52. 2002
  7. ncbi request reprint Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease
    Larisa H Cavallari
    Larisa H Cavallari, PharmD Department of Pharmacy Practice, University of Illinois at Chicago, 833 South Wood Street, Room 164, Chicago, IL 60612, USA
    Curr Treat Options Cardiovasc Med 11:191-200. 2009
  8. ncbi request reprint Warfarin pharmacogenomics
    Larisa H Cavallari
    University of Illinois at Chicago, Department of Pharmacy Practice, Chicago, IL 60612, USA
    Curr Opin Mol Ther 11:243-51. 2009
  9. doi request reprint Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
    Pharmacotherapy 30:1-9. 2010
  10. doi request reprint Genetic and clinical predictors of warfarin dose requirements in African Americans
    L H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 87:459-64. 2010

Collaborators

Detail Information

Publications36

  1. pmc Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois, Chicago, IL 60612 7230, USA
    Pharmacogenet Genomics 22:152-8. 2012
    ..This study tested the hypothesis that the γ-glutamyl carboxylase (GGCX) genotype contributes to warfarin dose requirements greater than 7.5 mg/day in an African American population...
  2. pmc Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure
    Adam Bress
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA
    PLoS ONE 8:e71268. 2013
    ..In addition, increased West African ancestry was associated with decreased serum aldosterone levels, potentially providing an explanation for the lower risk for AF observed among African Americans. ..
  3. pmc Role of cytochrome P450 genotype in the steps toward personalized drug therapy
    Larisa H Cavallari
    Department of Pharmacy Practice Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
    Pharmgenomics Pers Med 4:123-36. 2011
    ..As such, P450 genotyping is likely to lead the way in the clinical implementation of pharmacogenomics. This review discusses variability in the CYP2C9, CYP2C19, and CYP2D6 genes and the implications of this for drug efficacy and safety...
  4. ncbi request reprint Tailoring drug therapy based on genotype
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, USA
    J Pharm Pract 25:413-6. 2012
    ..In the future, it is possible that individuals will be broadly genotyped so that genetic information can guide drug therapy decisions throughout their lifetime...
  5. pmc The future of warfarin pharmacogenetics in under-represented minority groups
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, 833 South Wood Street, Chicago, IL 60612 7230, USA
    Future Cardiol 8:563-76. 2012
    ..These data suggest that it is important to consider variants specific for African-Americans when implementing genotype-guided warfarin dosing in this population...
  6. ncbi request reprint Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management
    Larisa M Humma
    Department of Pharmacy Practice, University of Illinois at Chicago, 833 South Wood Street, Room 164, Chicago, IL 60612, USA
    Am J Health Syst Pharm 59:1241-52. 2002
    ..Pharmacogenetics has many possible applications in the drug therapy of cardiovascular diseases. Much more must be learned, however, before pharmacogenetic factors can be routinely incorporated into therapeutic decisions...
  7. ncbi request reprint Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease
    Larisa H Cavallari
    Larisa H Cavallari, PharmD Department of Pharmacy Practice, University of Illinois at Chicago, 833 South Wood Street, Room 164, Chicago, IL 60612, USA
    Curr Treat Options Cardiovasc Med 11:191-200. 2009
    ....
  8. ncbi request reprint Warfarin pharmacogenomics
    Larisa H Cavallari
    University of Illinois at Chicago, Department of Pharmacy Practice, Chicago, IL 60612, USA
    Curr Opin Mol Ther 11:243-51. 2009
    ..The results of ongoing or future multicenter clinical trials are expected to clarify the role of pharmacogenomics in the management of warfarin therapy...
  9. doi request reprint Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
    Pharmacotherapy 30:1-9. 2010
    ..To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure...
  10. doi request reprint Genetic and clinical predictors of warfarin dose requirements in African Americans
    L H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 87:459-64. 2010
    ..No other VKORC1, CYP4F2, or APOE polymorphism contributed to the variance. The inclusion of additional CYP2C9 variants may improve the predictive ability of warfarin dosing algorithms for African Americans...
  11. doi request reprint Pharmacogenomics of warfarin dose requirements in Hispanics
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, 833 S Wood St, Chicago, IL 60612, USA
    Blood Cells Mol Dis 46:147-50. 2011
    ..s...
  12. doi request reprint Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
    Pharmacotherapy 31:785-92. 2011
    ..To test the hypothesis that genotypes for proteins affecting vitamin K availability influence the duration of time required to achieve a stable warfarin dose in African-American patients...
  13. ncbi request reprint Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
    J Renin Angiotensin Aldosterone Syst 9:146-53. 2008
    ..We investigated whether MR gene expression influences renal fibrosis and MR antagonist response in a two-kidney, one-clip hypertensive rat model...
  14. doi request reprint Predictors of unstable anticoagulation in African Americans
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, 833 S Wood St, Room 164, Chicago, IL 60612 7230, USA
    J Thromb Thrombolysis 27:430-7. 2009
    ..We sought to identify contributors to unstable anticoagulation in African Americans...
  15. ncbi request reprint Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612 7230, USA
    Pharmacotherapy 24:750-6. 2004
    ....
  16. ncbi request reprint Sex difference in the antiplatelet effect of aspirin in patients with stroke
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612 7230, USA
    Ann Pharmacother 40:812-7. 2006
    ..The factors contributing to this variability are not well defined...
  17. ncbi request reprint Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy University of Illinois at Chicago, Chicago, IL 60612 7230, USA
    Congest Heart Fail 13:275-9. 2007
    ....
  18. ncbi request reprint Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Illinois 60612 7230, USA
    Pharmacotherapy 27:801-12. 2007
    ..To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure...
  19. ncbi request reprint Racial differences in potassium response to spironolactone in heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612 7230, USA
    Congest Heart Fail 12:200-5. 2006
    ..7 to 1.6 mEq/L) in Caucasians, but only 0.1 mEq/L (range, -0.8 to 0.9 mEq/L) in African Americans; p < 0.01. These data suggest that African Americans with heart failure may be less responsive to the renal effects of spironolactone...
  20. pmc Role of pharmacogenomics in the management of traditional and novel oral anticoagulants
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois 60612 7230, USA
    Pharmacotherapy 31:1192-207. 2011
    ..These data, once known, could be of great importance as routine monitoring parameters for these agents are not available...
  21. pmc CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects
    Larisa H Cavallari
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Illinois 60612, USA
    Pharmacogenet Genomics 23:228-31. 2013
    ..These data suggest that promoter region polymorphisms inherited with 449G>A decrease CYP2C9 expression and contribute to CYP2C9*8 effects on warfarin clearance and dose requirements...
  22. doi request reprint Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke
    Kathryn M Momary
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Ill, USA
    Cerebrovasc Dis 27:585-93. 2009
    ..We sought to determine whether cyclooxygenase-1 (PTGS1) genotype is associated with the ability of aspirin to inhibit platelet aggregation in patients at risk for stroke...
  23. pmc Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans
    Adam Bress
    Department of Pharmacy Practice, University of Illinois at Chicago, 833 S Wood St, Rm 164, Chicago, IL 60612 7230, USA
    Pharmacogenomics 13:1925-35. 2012
    ..The objective of this study was to determine the additional contribution of NQO1 and CYP4F2 genotypes to warfarin dose requirements across two racial groups after accounting for known clinical and genetic predictors...
  24. pmc Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
    Minoli A Perera
    Section of Genetic Medicine, Department of Medicine, University of Chicago, IL, USA
    Lancet 382:790-6. 2013
    ..We aimed to identify additional variants contributing to warfarin dose requirements in African Americans...
  25. pmc Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
    Danxin Wang
    Department of Pharmacology, Program in Pharmacogenetics, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Blood 112:1013-21. 2008
    ..Increased warfarin dose requirement in blacks was accounted for by lower frequency of the -1639 A allele. Therefore, -1639G>A is a suitable biomarker for warfarin dosing across ethnic populations...
  26. doi request reprint Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population
    Beth Nochowitz
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, USA
    Ann Pharmacother 43:1165-72. 2009
    ..Poor adherence to warfarin therapy is a major contributor to subtherapeutic anticoagulation...
  27. pmc The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease
    Stacy S Shord
    Department of Pharmacy Practice, University of Illinois, College of Pharmacy MC 886, 833 S Wood Street, Room 164, Chicago, IL 60612, USA
    Eur J Clin Pharmacol 65:651-8. 2009
    ..We conducted a prospective, open-label study in 54 adult subjects with sickle cell disease to determine the relationship between morphine concentrations, cytochrome P450 (CYP) 2D6 genotype, and clinical outcomes...
  28. ncbi request reprint New treatment option for heart failure patients: eplerenone
    Mary Ross Southworth
    Departments of Pharmacy Practice and Medicine, University of Illinois at Chicago, 60612, USA
    J Cardiovasc Nurs 19:390-5. 2004
    ..Eplerenone may be considered as part of the therapeutic plan in patients who have suffered a myocardial infarction and demonstrate evidence of heart failure...
  29. pmc A pharmacogenetics service experience for pharmacy students, residents, and fellows
    Katarzyna Drozda
    College of Pharmacy, University of Illinois at Chicago, Chicago, IL
    Am J Pharm Educ 77:175. 2013
    ..To utilize a comprehensive, pharmacist-led warfarin pharmacogenetics service to provide pharmacy students, residents, and fellows with clinical and research experiences involving genotype-guided therapy...
  30. pmc Feasibility of implementing a comprehensive warfarin pharmacogenetics service
    Edith A Nutescu
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL
    Pharmacotherapy 33:1156-64. 2013
    ..To determine the procedural feasibility of a pharmacist-led interdisciplinary service for providing genotype-guided warfarin dosing for hospitalized patients newly starting warfarin...
  31. pmc Warfarin dose requirements in a patient with the CYP2C9*14 allele
    Yee Ming Lee
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612 7230, USA
    Pharmacogenomics 15:909-14. 2014
    ..He reached a therapeutic international normalized ratio on day 5, which was maintained over the following week. This report adds to the limited data of the effects of the CYP2C9*14 allele on warfarin dose requirements. ..
  32. ncbi request reprint Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography
    Christina L Aquilante
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Am J Cardiol 94:535-8. 2004
    ..Gender and racial differences in blood pressure response merit consideration as potential contributors to the suboptimal response in dobutamine stress testing...
  33. ncbi request reprint Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies
    Tara Engeman Andrisin
    Department of Pharmacy Practice, Center for Pharmacogenomics, University of Florida, Gainesville 32610 0486, USA
    Pharmacotherapy 22:954-60. 2002
    ..To determine long-term stability, quantity, and quality of genomic DNA samples collected in buccal cells by the mouthwash method, for use in pharmacogenetic studies...
  34. ncbi request reprint Response to renin-angiotensin system antagonists in hypertensive black subjects
    Larisa M Humma
    J Am Coll Cardiol 42:1141; author reply 1141-2. 2003
  35. ncbi request reprint Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women's Ischemic Syndrome Evaluation Study
    Larisa M Humma
    Department of Pharmacy Practice, University of Florida, Gainesville 32610 0486, USA
    Pharmacotherapy 22:939-46. 2002
    ..To determine the pharmacodynamic parameters of dobutamine during dobutamine stress echocardiography (DSE) and to determine how beta-blocker withdrawal the evening before DSE affects responses to dobutamine during DSE...
  36. ncbi request reprint Pharmacogenetics of cardiovascular drugs
    Julie A Johnson
    Center for Pharmacogenomics, University of Florida, USA
    Brief Funct Genomic Proteomic 1:66-79. 2002
    ....